Inclusion Criteria for M/S Asthma, CRSwNP, and AD

To be included in the analyses, patients with M/S type 2 asthma needed to have persistent use (≥ 3 months) of medium-to-high dose inhaled corticosteroid/long-acting beta-2 agonist and ≥ 1 exacerbation, with either blood eosinophil count ≥ 150 cells/μL or intermediate/high fractional exhaled nitric oxide (based on physician judgement); or alternatively were included if they had persistent (≥ 3 months) maintenance oral corticosteroid (OCS) dependence. Patients with M/S CRSwNP were required to have maintenance or acute OCS in their treatment history or ≥ 1 prior sinus surgery for CRSwNP and M/S “nasal blockage” in the past 2 weeks. Patients with M/S AD were required to have received topical therapy (corticosteroid of any strength, crisaborole, and/or a calcineurin inhibitor) and either had disease described by their physician as changeable, deteriorating slowly, deteriorating rapidly or were suitable candidates for a systemic therapy (immunosuppressants or injectable corticosteroids or biologics) according to their physician; or alternatively were currently receiving or had previously received a systemic therapy for AD.